Home / Intelligence / Webinars / Annual State of Global Market Access Webinar
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the impacts for pharma manufacturers.
Register for this webinar for a deeper dive into a few trends in the white paper. Join experts from our Evidence, Value, Access & Pricing team, Maximilian Hunt, Partner, Jeff Skaar, Managing Director, and Ismail Ismailoglu, Principal, for an insightful discussion on the hot topics below.
Key Webinar Topics
- Cell & gene therapy expansion and other new drug modalities: The evolving evidence requirements to demonstrate value for these potentially one-time/curative, high-priced therapies
- How the greater availability of real-world evidence is shaping and impacting payer evidence expectations
- The significant increase in market delays and withdrawals due to lower reimbursement opportunity—driven by both policy and cost cutting in U.S. and EU markets—and the implications for manufacturers
In Case You Missed It
Click here to read our white paper entitled Annual State of Global Market Access.
Featuring
Maximilian Hunt
Partner,
Value, Access & Pricing
Jeff Skaar
Managing Director,
Evidence Strategy
Ismail Ismailoglu
Principal,
Value, Access & Pricing
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve […]
Read More
Blog
Learnings to Kick-Start 2025: Joint Clinical Assessments and Health Technology Assessments
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or […]
Read More